Abd EL-Rehim DM, Pinder SE, Paish CE, et al (2004). “Expression of luminal and basal cytokeratins in human breast carcinoma”. J Pathol, 203, pp:661-671.
Adedayo A., Jessica M., Robert T., et al. (2009). “Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival”. Clinical Medicine & Research, Volume 7, Number 1-2, pp: 4 -13.
Ahlin C. Aaltonen K., (2007). “Ki67 and cyclin A as prognostic factors in early breast cancer.What are the optimal cut-off values?” Histopathology; 51, pp: 491–498.
Allred DC, Bustamante MA, Daniel CO (1990). “Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance”. Arch ...
Asselin-Labat ML, Vaillant F, Sheridan JM, et al (2010). Control of mammary stem cell function by steroid hormone signalling. Nature; 465; pp: 798–802.
Awadelkarim K D, Arizzi C, et al (2008). “Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa”. Histopathology 52, pp: 445–456
Barabe F, Kennedy JA, Hope KJ, et al (2007). “Modeling the initiation and progression of human acute leukemia in mice”. Science 316, pp: 600–604.
Barbareschi M, Pecciarini L, Cangi MG (2001), et al. “p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast”. Am J Surg Pathol, 25 pp:1054-1060.
Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, et al (2008). “Her-2/neu amplifi cation and breast cancer survival: Results from the Shanghai breast cancer study”. Oncol Rep 19, pp:1347-54.
Bloom, H.J. and Richardson W.W. (1957) “Histological grading and prognosis in breast cancer”. Br. J. Cancer 11, pp: 359-377.
Bocker W, Moll R, Poremba C, et al (2002). “Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept”. Lab Invest 82, pp:737-746.
Bofin A M. (Anna), Ytterhus B., Martin C., et al (2004). “Detection and Quantitation of HER-2 Gene Amplification and Protein Expression in Breast Carcinoma”. Am J Clin Pathol 122 pp:110-119
Bombonati A, Sgroi DC., et al (2011). “The molecular pathology of breast cancer progression” . J Pathol 223, pp: 307–317
Brenton JD., Lisa A.C., Ahmed A A., and Carlos C. (2005). “Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?” J Clin Oncol 23, pp:7350-7360.
Brunelli M., Manfrin E., et al (2008). “HER-2/neu Assessment in Breast Cancer Using the Original FDA and New ASCO/CAP Guideline RecommendationsImpact on Selecting Patients for Herceptin Therapy”. Am J Clin Pathol 129, pp:907-911
Carey LA, Dees EC, Sawyer L, et al (2004): “The triple negative paradox: Primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype”. San Antonio Breast Cancer Symposium.
Carey LA, Perou CM, Livasy CA. (2006). “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study”. J. Am. Med. Assoc 295 pp: 2492–2502.
Chieh L., Ming L., et al (2005). “erb-b2 Amplification by Fluorescence In Situ Hybridization in Breast Cancer Specimens Read as 2+ in Immunohistochemical Analysis”. Am J Clin Pathol;124:97-102
Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, et al (2003). “A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplifi cation by fluorescence in situ hybridization in white and Korean patients with early-onset breast c...
Clarke MF, Dick JE, Dirks PB, et al (2006). “Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells”. Cancer Res; 66, pp: 9339–9344.
Cobleigh MA, Vogel CL, Tripathy D, et al (1999). “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metas...
Colditz GA, Rosner BA, (2004): “Risk factors for breast cancer according to estrogen and progesterone receptor status”. J Natl Cancer Inst 96, pp:218-228,
College of American Pathologists, Cell Markers and Cytogenetics Committees (2002). “Clinical laboratory assays for HER- 2/neu amplification and overexpression”. Arch Pathol Lab Med.;126:803-808
Dolan M., Snover D (2005). “Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice”. Am J Clin Pathol;123, pp:766-770
Donegan W.L., Spartt J.S. Cancer of the breast. Fifth edition (2002). Molecular biology of breast cancer. Elservier Science. pp 181-198
Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, (2003). “Stem cells in normal breast development and breast cancer”. Cell Prolif, 36, pp:59-72.
Dontu G, El-Ashry D, Wicha MS (2004). “Breast cancer, stem/progenitor cells and the estrogen receptor”. Trends Endocrinol Metab; 15, pp: 193–197.
Douglas-Jones AG, Gupta SK, Attanoos RL, (1996). “A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast: correlation with grade of associated invasive carcinoma”. Histopathology; 29, pp:397–409.
Dowsett M, Bartlett J, Ellis JO, et al (2003). “Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres”. J Pathol;199, pp:418-23.
Dowsett M, Urruticoechea A., Smith I.E., (2005). “Proliferation Marker Ki-67 in Early Breast Cancer” J Clin Oncol 23, pp:7212-7220.
Eccles SA (2001). “The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis”. J Mammary Gland Biol Neoplasia; 6 pp:393-406.
Elston CW, Ellis IO (2002). “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up”. Histopathology; 41, pp: 151–152.
Farmer P, Bonnefoi H, Becette V, et al (2005). “Identification of molecular apocrine breast tumours by microarray analysis”. Oncogene; 24, pp: 4660–4671.
Fornier M, Risio M, Van Poznak C, et al (2002). “HER2 testing and correlation with efficacy of Trastuzumab therapy”. Oncology; 16, pp:1340- 52.
Fowble B.L., Schultz D.J., Overmoyer B., Solin L.J., Fox K., (1994), “The influence of young age on outcome in early stage breast cancer”, International Journal of Radiation Oncology, Biology, Physics, 309(1), pp. 23-33
Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome”. Cell Stem Cell; 1, pp: 555–567.
GLOBOCAN (2008). Breast Cancer Incidence and Mortality World wide in 2008.
Goldhirsch A, Wood WC., Coates A S., Gelber RD., Sennet HJ., (2011). “Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer”. Annal...
Hadi Y., Lynn C.G., Todd S.B., Robert W (2004). “Testing in Breast Cancer Using Parallel Tissue-Based Methods”. JAMA; 291, pp:1972-1977
Harris J.R., Lippman M.E., Morrow M., Osborne C.K., (2000), Diseases of the breast, 2nd Edition, Lippincott Williams & Wilkins, Philadelphia, pp: 511-514.
Heimann R, Hellman S (1998). “Aging, progression, and phenotype in breast cancer”. J Clin Oncol;16, pp:2686–2692
Hicks DG., Raymond R.T (2005). “Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines”. Human Pathology 36, pp: 250– 261.
Janet S.W., Jeyanthi R., Ellis L.,(2004). “HER-2/neu Evaluation in Breast Cancer Are We There Yet?”. Am J Clin Pathol;121, pp:S33-S49.
Jeong S. H., Dengfeng C., Kyle H. et al (2011). “Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast carcinomas, and High Expression of Ki-67 but Not p53 Is Sign...
Jimenez RE, Wallis T, Tabasczka P, et al (2000). “Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization”. Mod Pathol.;13, pp:37-45.
Jones RL, Salter J, (2009).“The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer”. Breast Cancer Res Treat.;116, 53-68.
Joshi PA, Jackson HW, Beristain AG, et al (2010). Progesterone induces adult mammary stem cell expansion. Nature; 465; pp: 803–807.
Kakar S, Puangsuvan N, Stevens JM, et al (2000). “HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival”. Mol Diagn.;5, pp:199-207.
Kamangar F., Dores G.M., Anderson W.F. (2006). “Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World”. Journal of Clinical Oncolog...
Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M,(2008). “Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplifi cation in breast cancer”. Oncol Rep;19, pp:651-656.
Lacroix M., Toillon R.A. and Leclercq G (2006). “p53 and breast cancer, an update Endocrine-Related”. Cancer 13, pp: 293-325
Lebeau A, Deimling D, Kaltz C, et al (2001). “HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization”. J Clin Oncol.;19, pp:354-363.
Lindley R, Bulman A, Parsons P, et al (1989). “Histologic features predictive of an increased risk of early local recurrence after treatment of breast cancer by local tumor excision and radical radiotherapy”. Surgery;105, pp:13–20.
Lipponen P, Aaltomaa S, et al (1994). “Apoptosis in breast cancer as related to histopathological characteristics and prognosis”. Eur J Cancer;30, pp: 2068–2073.
Loi S, Haibe-Kains B, Desmedt C, (2007). “Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade”. J Clin Oncol; 25, pp: 1239-1246.
Love SM, Barsky SH.(2004). “Anatomy of the nipple and breast ducts revisited”. Cancer,101, pp:1947-1957.
Lusa L, McShane LM, (2007). “Challenges in projecting clustering results across gene expression-profiling datasets”. J Natl Cancer Inst; 99, pp: 1715-1723.
Mass R, Sanders C, Charlene K, et al (2000). “The concordance between the clinical trials assay and fluorescence in situ hybridization in the Herceptin pivotal trials”. Proc Am Soc Clin Oncol.;19, pp: 70-75.
McCarty WC, Sistrunk WE, (1922). “Life expectancy following radical amputation for carcinoma of the breast: A clinical and pathologic study of 218 cases”. Ann Surg;75, pp:61–69.
McCormick SR, Lillemoe TJ, Beneke J, et al (2002). “HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays”. Am J Clin Pathol.;117, pp:935-943.
Ménard S, Tagliabue E, Campiglio M, Pupa SM (2000). J Cell Phys;182, pp:150-162
Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T (2002). “Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections”. Mod Pathol, 15, pp:397-405.
Nagata Y, Lan KH, Zhou X, et al (2004): “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients”. Cancer Cell 6, pp:117-127
Nicolini A, Carpi A, Tarro G (2006). “Biomolecular markers of breast cancer”. Front Biosci.;11, pp:1818-1843.
Nielsen TO, Hsu FD, Jensen K et al (2004). “Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma”. Clin. Cancer Res; 10 pp:5367-5374.
Nishimura R, Nagao K, (1999). “Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis”. J Surg Oncol;71, pp:226–234.
Nixon A.J., Neuberg D., Hayes D.F., Gelman R., Connlly J.L., Schnitt S., Abner A., Recht A., Vicini F. and Harris J.R., (1994), “Relationship of patient age to pathologic features of the tumor and prognostis for patients with stage I or II breast canc...
Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W (2000). “Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast”. Histopathol 37, pp:232-40,
Pauletti G, Dandekar S, Rong H, et al (2000). “Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry”. J Clin Oncol;18, p...
Pece S, Tosoni D, Confalonieri S,.(2010). “Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content”. Cell; 140, pp: 62–73.
Perez EA, Roche PC, Jenkins RB,(2002). “HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization”. Mayo Clin Proc;77, pp:148 - 54.
Perou CM, Sorlie T, Eisen MB et al (2000). “Molecular portraits of human breast tumours”. Nature; 406, pp:747–752.
Petit T, Wilt M, Velten M, et al (2004). “Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy”....
Ponti D, Zaffaroni N, Capelli C, et al (2006). “Breast cancer stem cells: an overview”. Eur J Cancer; 42, pp: 1219-1224.
Priti L., Paulo A.S, Clifford A.H (2004),.”HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization”. Am J Clin Pathol;121, pp:631-636
Rakha E.A, Ellis I.O (2010). “Breast cancer prognostic classification in the molecular era: the role of histological grade”. Breast Cancer Research; 12, pp:207-11.
Rakha EA, El-Sayed ME, Green AR, et al (2007). “Prognostic markers in triple-negative breast cancer”. Cancer.;109, pp:25-32.
Rasmussen B. Andersson M.,(2008). “Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group in the period of 2002-2006. A nationwide study including correlation between HER-2 stat...
Ridolfi RL, Jamehdor MR, Arber JM (2000). “HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach”. Mod Pathol.;13, pp:866-873.
Rohit B., Sushil B. David J.D. et al (2010). “Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy”. Cancer;116, pp:1431–9.
Rosen, P.P. Rosen's Breast Pathology, 3rd Edition (2009) Invasive Duct carcinoma: Assessment of Prognosis, Morphologic Prognostic Markers, and Tumor Growth Rate. Lippincott Williams & Wilkins, pp: 358-404
Ross JS, Fletcher JA, Bloom KJ, (2003). “The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy”. The oncologist 8, pp: 307-325.
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, (2009). “The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine”. Oncologist;14; pp:320 – 68.
Rouzier R, Perou CM., et al (2005) “Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy”. Clin Cancer Res; 11:5678-5685.
Roylance R, Gorman P, Harris W, et al (1999). “Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer”. Cancer Res; 59: 1433–1436.
Schnitt SJ, Millis RR, (2007) The breast. In: Histology for Pathologists, 3rd Edition Lippincott Williams & Wilkins.
Seidman AD, Fornier M, Esteva FJ, et al (2001). “Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification”. J Clin Oncol.;19:2587-2595.
Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA (2002). “Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas”. J Pathol, 198:450-457.
Silverberg SG, Chitale AR (1978). “Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast”. Cancer;32:830–837.
Silverstein MJ, Lagios MD, Craig PH, et al (1996). “A prognostic index for ductal carcinoma in situ of the breast”. Cancer;77:2267–2274.
Simpson PT, Reis-Filho JS, Lambros MB, et al (2008). “Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas”. J Pathol; 215: 231–244.
Slamon DJ, Clark GM, et al (1987). “Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene”. Science;235:177 - 82.
Slamon DJ, Leyland-Jones B, Shak S, et al (2001). “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2”. N Engl J Med;344:783- 92.
Sorlie T, Perou CM, Tibshirani R, et al (2001): “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications”. Proc Natl Acad Sci U S A 98:10869- 10874,
Sorlie T, Tibshirani R, Parker J, (2003). “Repeated observation of breast tumor subtypes in independent gene expression data sets”. Proc Natl Acad Sci USA; 100: 8418–8423.
Sotiriou C, Neo SY, McShane LM, et al (2003). “Breast cancer classification and prognosis based on gene expression profiles from a population-based study”. Proc Natl Acad Sci USA; 100: 10393–10398.
Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. (2009). “Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of S...
Stanley R., Tamera J. L., et al. (2002). “Assessment by Immunohistochemical Analysisand Fluorescence In Situ Hybridization Comparison of HercepTest and PathVysion Commercial Assays”. Am J Clin Pathol;117:935-943
Tang P., Kristin A.S, David GH (2009) “Molecular Classification of Breast carcinomas by Immunohistochemical Analysis Are We Ready?” Diagn Mol Pathol 18, Number 3 pp:124-132.
Tavassoli F. A DP (2003). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. WHO: Geneva, 9–19.
Tedesco KL, Thor AD, Johnson DH, et al (2004). “Docetaxel combined with Trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial”. J Clin ...
Thang VH., Edneia., Van TT., Kamilla K., (2011). “HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry and automated silver enhanced in situ hybridization”. Acta Oncologica; 50, pp: 360–366
Trihia H, Murray S., et al (2003). “Ki-67 Expression in Breast carcinoma Its Association with Grading Systems, Clinical Parameters, and Other Prognostic Factors—A Surrogate Marker?” Cancer; 97, pp:1321–31.
Tubbs RR, Pettay JD, Roche PC, et al (2001). “Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message”. J Clin Oncol;19, pp:2714- 21.
Turner N, Tutt A, Ashworth A (2004): “Hallmarks of ‘BRCAness’ in sporadic cancers”. Nat Rev Cancer 4, pp:814-819.
Varshney D., Zhou Y., PhD, Geller SA., (2004), “Determination of HER-2 Status and Chromosome 17 Polysomy in Breast carcinomas Comparing HercepTest and PathVysion FISH Assay”. Am J Clin Pathol 121, pp:70-77
Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, et al (2007). “Evidence for a stem cell hierarchy in the adult human breast”. J Cell Biol; 177, pp: 87–101.
Voduc KD, Cheang MC, Tyldesley S, et al (2010). “Breast cancer subtypes and the risk of local and regional relapse”. J Clin Oncol; 28, pp: 1684–1691.
Vogel CL, Cobleigh MA, Tripathy D, et al (2002). “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer”. J Clin Oncol.;20, pp:719-726.
Wang S, Saboorian MH, Frenkel EP, et al (2002). “Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status”. Mod Pathol.;15, pp:137-145
Weidner N., Cote R.J., Suster S., Weiss L.M (2009), Modern Surgical Pathology, by Saunders, an imprint of Elsevier Inc.
Weigelt B, Mackay A, A’Hern R, et al (2010). “Breast cancer molecular profiling with single sample predictors: a retrospective analysis”. Lancet Oncol; 11: 339–349.
Wirapati P, Sotiriou C, Kunkel S, et al (2008). “Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures”. Breast Cancer Res.10:R65. doi:10.1186/ bcr2124.
Wolff AC. and et al (2007). “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer”. J Clin Oncol 25:118-145.
Yarden Y., et al, (2001) “Biology of HER2 and its importance in breast cancer”. Oncology 61, pp:1–13.
Yaziji H, Gown AM, Sneige N (2000). “Detection of stromal invasion in breast cancer: the myoepithelial markers”. Adv Anat Pathol, 7, pp:100-109.